Combined EGFR and c-src antisense oligodeoxynucleotides encapsulated with PAMAM denderimers inhibit HT-29 colon cancer cell proliferation

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 9, 2012, Pages 4751-4756

  Nourazarian, Ali Reza ^a   Najar, Ahmad Gholamhoseinian ^b   Farajnia, Safar ^c   Khosroushahi, Ahmad Yari ^d,e   Asl, Roghiyeh Pashaei ^d   Omidi, Yadollah ^d,f  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antisense; C Src; Colon cancer; EGFR; HT 29; PAMAM dendrimers

Indexed keywords

EID: 84874011455     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.9.4751     Document Type: Article

References (23)

1. Albertazzi L, SerresiI M, Albanese A, Beltram F (2010). Dendrimer internalization and intracellylar trafficking in living cells. Mol Pharm, 7, 680-8.
2. Beale G, HolliIns AJ, Benboubetra M, et al (2003). Gene silencing nucleic acids designed by scanning arrays:Anti- EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single Hybridization-accessible region using the same delivery system. J Drug Targeting, 7, 449-56.
3. Bowles TL, Parsons C, Muilenburg D, Bold RJ (2009). Targeted inhibition of AKT in pancreatic cancer. Curr Cancer Therapy Rev, 5, 288-95.
4. Bradford M (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72, 248-54.
5. Chapnick D, Warner L, Bernet J, RAO T, Liu X (2011). The TGFbeta and MAPK pathways in cancer progression. Cell and Biosci, 1, 42.
6. Eder I, Haag P, Bartsch G, Klocker H (2005). Gene therapy strategies in prostate cancer. Curr Gene Ther, 5, 1-10.
7. Ellis LM, Staley CA, LIU W, et al (1998). Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem, 273, 1052-7.
8. FINN R (2008). Targeting Src in breast cancer. Annals Oncol, 19, 1379-86.
9. Irby RB, Yeatman T (2000). Role of Src expression and activation in human cancer. Oncogene, 19, 5636-42.
10. Kopetz S (2007). Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic. Gastrointest Cancer Res, 1, 37-41.
11. Kumar R, SriniIvasan S, Pahari P, Rohr J, Damodaran C (2010). Activating stress-activated protein kinase-mediated cell death and inhibiting epidermal growth factor receptor signaling: a promising therapeutic strategy for prostate cancer. Mol Cancer Ther, 9, 2488-96.
12. LIEU C, Kopetz S (2010). The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy. Clin Colorectal Cancer, 9, 89-94.
13. Mukhopadhyay D, Tsiokas L, Zhou XM, et al (1995). Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature, 375, 577-81.
14. Nakhlband A, Barar J, Bidmeshkipour A, Heidari H, Omidi Y (2010). Bioimpacts of anti epidermal growth factor receptor antisense complexed with polyamidoamine dendrimers in human lung epithelial adenocarcinoma cells. J Biomed Nanotechnol, 6 360-9.
15. Nourazarian AR, Pashaie AR, Omidi Y, Gholamhoseinian NA(2012). c-Src antisense complexed with PAMAM denderimes decreases of c-Src expression and EGFRdependent downstream genes in the human HT-29 colon cancer cell line. Asian Pac J Cancer Prev, 13, 2235-40.
16. Omidi Y, Barar J (2009). Induction of human alveolar epithelial cell growth Factor receptors by dendrimeric nanostructure. Int J Toxicol, 28, 113-22.
17. Sabbah M, Emami S, Redeuilh G, et al (2008). Molecular signature and therapeutic perspective of the epithelialto- mesenchymal transitions in epithelial cancers. Drug Resistance Updates, 11, 123-51.
18. Summy JM, Gallick GE (2003). Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev, 22, 337-58.
19. Summy JM, Trevino JG, Lesslie DP, et al (2005). AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Cancer Ther, 4, 1900-11.
20. Talamonti M, Roh M, Curley S, Gallick G (1993). Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest, 91, 53-60.
21. Xiong H, Su WY, Liang QC, et al (2009). Inhibition of STAT5 induces G1 cell cycle arrest and reduces tumor cell invasion in human colorectal cancer cells. Lab Invest, 89, 717-25.
22. Yamaguchi M, Tanaka T, Waki M, et al (1997). Antisense src expression inhibits tyrosine phosphorylation of Shc and its association with Grb2 and Sos which leads to MAP kinase activation in U937 human leukemia cells. Leukemia, 11, 497-503.
23. Yavari K, Taghikhani M, Maragheh MG, Mesbahnamin SA, BabaieI MH (2009). Knockdown of IGF-IR by RNAi inhibits SW480 colon cancer cells growth in vitro. Arch Med Res, 40, 235-40.